Takeshi Ogura 1 , Daisuke Masuda 1 , Akira Imoto 1 , Toshihisa Takeushi 1 , Rieko Kamiyama 1 , Malak Mohamed 2 , Eiji Umegaki 1 , Kazuhide Higuchi 1 . Show Affiliations »
Abstract
BACKGROUND AND STUDY AIM: To minimize bile leakage and avoid possible death because of stent migration in endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS), we have recently combined EUS-HGS with EUS-guided antegrade stenting (EUS-AS) of the biliary obstruction using a novel uncovered metallic stent with a fine-gauge delivery system. In this pilot study, we evaluated the feasibility and adverse events associated with this combination therapy using the novel stent. PATIENTS AND METHODS: We performed EUS-guided antegrade stenting and hepaticogastrostomy in 12 consecutive patients. RESULTS: The novel EUS-AS stent was placed across the ampulla of Vater in 8 patients and above the ampulla in 4. Technical and functional success rates were 100 %. In addition, the insertion of the first stent was achieved in all patients without dilation of the fistula between stomach and intrahepatic bile duct. Although 1 patient experienced mild pancreatitis, adverse events such as bile peritonitis or stent dysfunction did not occur during follow-up (mean 122 days, range 62 - 210 days). CONCLUSION: This method appears to safely and effectively avoid adverse events associated with EUS-HGS. © Georg Thieme Verlag KG Stuttgart · New York.
BACKGROUND AND STUDY AIM: To minimize bile leakage and avoid possible death because of stent migration in endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS), we have recently combined EUS-HGS with EUS-guided antegrade stenting (EUS-AS) of the biliary obstruction using a novel uncovered metallic stent with a fine-gauge delivery system. In this pilot study, we evaluated the feasibility and adverse events associated with this combination therapy using the novel stent. PATIENTS AND METHODS: We performed EUS-guided antegrade stenting and hepaticogastrostomy in 12 consecutive patients . RESULTS: The novel EUS-AS stent was placed across the ampulla of Vater in 8 patients and above the ampulla in 4. Technical and functional success rates were 100 %. In addition, the insertion of the first stent was achieved in all patients without dilation of the fistula between stomach and intrahepatic bile duct . Although 1 patient experienced mild pancreatitis , adverse events such as bile peritonitis or stent dysfunction did not occur during follow-up (mean 122 days, range 62 - 210 days). CONCLUSION: This method appears to safely and effectively avoid adverse events associated with EUS-HGS. © Georg Thieme Verlag KG Stuttgart · New York.
Entities: Disease
Species
Mesh: See more »
Year: 2014
PMID: 24573771 DOI: 10.1055/s-0034-1365020
Source DB: PubMed Journal: Endoscopy ISSN: 0013-726X Impact factor: 10.093